Skip to main content

Advertisement

Table 1 Characteristics of participants

From: Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET

Variables AD N = 32 NC N = 23 p values
global CDR frequency 0/0.5/1/2/3 0 / 24 / 7 / 1 / 0 23 / 0 / 0 / 0 / 0 < 0.001
CDR-SOB mean ± SD (range) 3.5 ± 1.84 (0.5–9) 0.0 ± 0.00 (0.0–0.0) < 0.001
MMSE score mean ± SD (range) 23.6 ± 4.37 (9–29) n = 31 29.5 ± 0.79 (28–30) < 0.001
Sex male / female 14 / 18 18 / 5 0.011
Age in years mean ± SD (range) 71.5 ± 4.70 (61–82) 64.7 ± 9.16 (50–85) 0.002
ApoE ε4 allele frequency 0/1/2/n.a. 9 / 15 / 4 / 4 15 / 8 / 0 0.010
CSF-Aβ42 levels [ng/l] mean ± SD (range) 516 ± 145.6 (260–930) 1014 ± 199.0 (668–1354) < 0.001*
42/Aβ40 ratios mean ± SD (range) 0.040 ± 0.0094 (0.020–0.061) 0.067 ± 0.0096 (0.051–0.0813) < 0.001*
CSF t-tau levels [ng/l] mean ± SD (range) 588 ± 334 (166–1650) 182 ± 41.3 (108–266) < 0.001*
CSF p-tau levels [ng/l] mean ± SD (range) 74.8 ± 32.5 (36–176) 35.5 ± 7.48 (23–53) 0.001*
CSF-KLK6 ng/ml mean ± SD (range) 321 ± 115.8 (132–663) 220 ± 62.4 (101–344) < 0.001*
CSF-KLK8 ng/ml mean ± SD (range) 0.163 ± 0.026 (0.12–0.22) 0.157 ± 0.0580 (0.10–0.37) 0.637*
CSF-KLK10 ng/ml mean ± SD (range) 0.665 ± 0.2338 (0.22–1.11) 0.484 ± 0.0249 (0.08–0.95) 0.008*
  1. p values: results of Mann-Whitney-U test or (*) t-test, respectively. In five patients, CDR was rated due to doctor’s letter, and one patient underwent the Montreal Cognitive Assessment test (MOCA test) instead of the MMSE
  2. AD patients with Alzheimer’s disease, NC cognitively normal controls, SD standard deviation, CDR clinical dementia rating scale, SOB sum of boxes, GLO global, MMSE Mini-Mental State Examination, ApoE Apolipoprotein E, CSF cerebrospinal fluid, β-amyloid, KLK kallikrein related peptidase